Get the Stockscreener App
17.35
14.66%
-2.98
Pre-market:
17.69
0.34
+1.96%
Galecto Inc stock is traded at $17.35, with a volume of 200.11K.
It is down -14.66% in the last 24 hours and up +83.99% over the past month.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
See More
Previous Close:
$20.33
Open:
$19.3
24h Volume:
200.11K
Relative Volume:
0.06
Market Cap:
$22.98M
Revenue:
-
Net Income/Loss:
$-38.35M
P/E Ratio:
-11.97
EPS:
-1.45
Net Cash Flow:
$-36.91M
1W Performance:
-37.68%
1M Performance:
+83.99%
6M Performance:
+466.99%
1Y Performance:
+198.62%
1-Day Range:
$16.82
$19.80
1-Week Range:
$16.82
$28.30
52-Week Range:
$2.01
$33.60
Galecto Inc Stock (GLTO) Company Profile
Name
Galecto Inc
Sector
Industry
Phone
45-70-70-52-10
Address
75 STATE STREET, BOSTON
Compare GLTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLTO
Galecto Inc
|
17.35 | 32.38M | 0 | -38.35M | -36.91M | -1.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.32 | 106.82B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.00 | 73.86B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.79 | 60.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.50 | 56.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
199.64 | 43.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Galecto Inc Stock (GLTO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | BofA Securities | Buy |
| Nov-23-20 | Initiated | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | SVB Leerink | Outperform |
Galecto Inc Stock (GLTO) Latest News
Can Galecto Inc. stock deliver surprise earnings beatCEO Change & Free AI Powered Buy and Sell Recommendations - newser.com
Is Galecto Inc. stock gaining market shareJuly 2025 Action & Fast Momentum Stock Entry Tips - newser.com
Can Galecto Inc. stock weather global recessionTrade Entry Summary & Fast Gaining Stock Strategy Reports - newser.com
How Galecto Inc. stock performs in rising dollar environmentMarket Sentiment Review & Safe Capital Growth Stock Tips - newser.com
Can Galecto Inc. stock deliver consistent earnings growthMarket Sentiment Review & Safe Capital Preservation Plans - newser.com
Galecto, Inc. (GLTO) -3.02% in Pre-market: Focus on Recent Acquisition Announcement - Stocks Telegraph
Is Galecto Inc. stock attractive for growth ETFsJuly 2025 Price Swings & Verified Stock Trade Ideas - newser.com
Wall Street Zen Upgrades Galecto (NASDAQ:GLTO) to Hold - Defense World
Wall Street analysts’ outlook for Galecto Inc (GLTO) - Setenews
Galecto Acquires Damora Therapeutics and Secures $285 Million PIPE Investment - Global Legal Chronicle
Will Galecto Inc. stock maintain dividend yieldJuly 2025 Volume & AI Driven Price Forecasts - newser.com
Combining price and volume data for Galecto Inc.Bond Market & Consistent Profit Trade Alerts - newser.com
Will Galecto Inc. see short term momentumJuly 2025 Catalysts & Safe Entry Momentum Stock Tips - newser.com
Is Galecto Inc. meeting your algorithmic filter criteriaQuarterly Risk Review & Long-Term Capital Growth Strategies - newser.com
Small Cap Stocks To ResearchNovember 10th - MarketBeat
Small Cap Stocks To Watch TodayNovember 11th - MarketBeat
Galecto (GLTO) Stock Price, Quote, News & History - Benzinga
Can Galecto Inc. stock hit analyst price targetsJuly 2025 Breakouts & AI Optimized Trade Strategies - newser.com
What analysts say about Galecto Inc stockStock Buy Signals & Analysts Are Raving About These Shares - earlytimes.in
Why Galecto Inc. stock remains undervalued2025 Performance Recap & Weekly High Momentum Picks - newser.com
US: Galecto acquires Damora Tx and raises US$285m from Series C - Investors in Healthcare
Small Cap Stocks To Research – November 10th - Defense World
A Week Is A Long Time In Biotech, Just Ask Galecto - Citeline News & Insights
Biotech Mergers And Trial Successes Send Shares Higher - Finimize
There is no doubt that Galecto Inc (GLTO) ticks all the boxes. - Setenews
Galecto Stock Surges Premarket After Damora Acquisition — Retail Bulls Predict Another Massive Rally - Asianet Newsable
S&P 500, Nasdaq and Dow Jones see big rise as heavyweight tech stocks witness rebound: Galecto sees 250% gain, Sonder Holdings plunges; check top gainers and losers on November 10 and here’s how top indices performed - The Economic Times
One Stock. Thirty Minutes. One Parabolic Move. - StocksToTrade
This Penny Stock Just Quadrupled. Should You Buy It Now? - Barchart.com
Galecto Completes Acquisition of Damora Therapeutics - MSN
GLTO, MOVE: two penny stocks quadrupled today – but should you buy? - CryptoRank
Galecto Inc Stock (GLTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):